Lightnews — Scholar-powered news

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 3h

Brief report on differential toxicity of legacy and second-generation PFAS on dopaminergic neurons and mitochondria https://www.biorxiv.org/content/10.1101/2025.10.08.681169v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 11h

Structural hormesis in protein aggregation: A minimal mechanistic model https://www.biorxiv.org/content/10.1101/2025.10.07.681066v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 12h

Planarian behavioral screening is a useful invertebrate model for evaluating seizurogenic chemicals https://www.biorxiv.org/content/10.1101/2025.10.07.680963v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 1d

Structure-Guided Optimization and Functional Characterization of Small Molecule Antagonists Targeting CD28 Costimulation https://www.biorxiv.org/content/10.1101/2025.10.06.680836v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 1d

Glycan Profiling Identifies Chondroitin-4-sulfate as a Biomarker for Platinum Response and Therapeutic Target in Ovarian Cancer https://www.biorxiv.org/content/10.1101/2025.10.06.675352v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 1d

Enhanced splicing modulation by NMA-modified antisense oligonucleotides https://www.biorxiv.org/content/10.1101/2025.10.06.680653v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 2d

Exposure of male mice to nicotine leads to metabolic dysfunction in their male and female offspring https://www.biorxiv.org/content/10.1101/2025.10.04.680466v1

1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 3d

Investigation of anti-SARS CoV-2 multimeric bicyclic peptide inhibitors in a range of pre-clinical therapeutic settings https://www.biorxiv.org/content/10.1101/2025.10.03.680220v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 3d

Dabigatran prevents lipopolysaccharide mediated apoptosis in zebrafish through a thrombin independent mechanism https://www.biorxiv.org/content/10.1101/2025.10.03.680206v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 4d

The Critical and Unexpected Role of a Methyl Group in Interleukin-17A Inhibitors https://www.biorxiv.org/content/10.1101/2025.10.02.680113v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 4d

UGT35B1 is the principal enzyme mediating nicotine glycosylation in Drosophila melanogaster https://www.biorxiv.org/content/10.1101/2025.10.03.680272v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 5d

Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1 https://www.biorxiv.org/content/10.1101/2025.10.02.679991v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 7d

Large-Scale Structure-Based Virtual Screening Identifies Diverse KNa1.1 (KCNT1) Potassium Channel Inhibitors https://www.biorxiv.org/content/10.1101/2025.09.30.679465v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 8d

Application-dependent assessment of the human exposure potential to microplastics https://www.biorxiv.org/content/10.1101/2025.09.29.679164v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 8d

Overcoming rapaprotin resistance through inhibition of P-glycoprotein https://www.biorxiv.org/content/10.1101/2025.09.28.679086v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 9d

Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight Loss https://www.biorxiv.org/content/10.1101/2025.09.26.678829v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 10d

NLX-112 is anti-inflammatory, upregulates GDNF and is neuroprotective against MPTP-induced nigrostriatal dopaminergic degeneration in mice https://www.biorxiv.org/content/10.1101/2025.09.25.678507v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 12d

Variability and uncertainty of data from genotoxicity Test Guidelines: What we know and why it matters. https://www.biorxiv.org/content/10.1101/2025.09.24.677002v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 13d

Late treatment initiation leads to reduced antiviral potency https://www.biorxiv.org/content/10.1101/2025.09.24.678199v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 13d

Target validation uncouples TSPO from 19-Atriol-mediated inhibition of steroidogenesis and reveals true enzymatic targets https://www.biorxiv.org/content/10.1101/2025.09.25.678677v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 13d

FDA-approved drug repurposing in zebrafish identifies thyroid hormone and other compounds as potential antithrombotics https://www.biorxiv.org/content/10.1101/2025.09.23.677920v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 13d

On the utilisation and characterisation of external biotransformation systems in in vitro toxicology: a critical review of the scientific literature with guidance recommendations https://www.biorxiv.org/content/10.1101/2025.09.23.677684v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 13d

Persistence of florpyrauxifen-benzyl in sediments following application to a large oligotrophic lake to control Eurasian watermilfoil https://www.biorxiv.org/content/10.1101/2025.09.23.678083v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 13d

In Vitro Evidence to Support Amphotericin B and Flucytosine Combination Therapy for Talaromycosis https://www.biorxiv.org/content/10.1101/2025.09.23.677804v1

bioRxiv Pharmacology and Toxicology @biorxiv-pharma.bsky.social · 14d

Elucidating the potential carcinogenic molecular mechanisms of parabens in head and neck squamous cell carcinoma through network toxicology and molecular docking https://www.biorxiv.org/content/10.1101/2025.09.22.677916v1